Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection, for cats

Krajina: Írsko

Jazyk: angličtina

Zdroj: HPRA (Health Products Regulatory Authority)

Aktívna zložka:

Feline calicivrus, strain f9 live attenuated; Feline herpes virus type 1, strain g2620a live attenuated; Feline panleucopenia virus, strain mw-1 live attenuated

Dostupné z:

Intervet Ireland Limited

ATC kód:

QI06AD04

INN (Medzinárodný Name):

Feline calicivrus, strain f9 live attenuated; Feline herpes virus type 1, strain g2620a live attenuated; Feline panleucopenia virus, strain mw-1 live attenuated

Dávkovanie:

.

Forma lieku:

Lyophilisate and solvent for suspension for injection

Typ predpisu:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutické skupiny:

Cats

Terapeutické oblasti:

feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus

Terapeutické indikácie:

Immunological - Live Vaccine

Stav Autorizácia:

Authorised

Dátum Autorizácia:

2007-02-28

Súhrn charakteristických

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Tricat Trio, lyophilisate and solvent for suspension for
injection, for cats
Nobivac RCP (AT, DE)
Nobivac Tricat Novum (ES)
Nobivac Tricat Novum vet (SE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (1 ml) of reconstituted vaccine contains:
ACTIVE SUBSTANCES
:
Live attenuated feline calicivirus, strain F9:

10
4.6
PFU
1
;
Live attenuated feline rhinotracheitis virus, strain G2620A:

10
5.2
PFU
1
;
Live attenuated feline panleucopenia virus, strain MW-1:

10
4.3
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
:
Cell Culture Infectious Dose 50%
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS_ _
_ _
Lyophilisate:
_ _
Disodium phosphate dihydrate
_ _
Hydrolysed gelatin
_ _
Pancreatic digest of casein
_ _
Sorbitol
Solvent:
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections
Lyophilisate: off -white pellet.
Solvent: clear colourless solution.
3.
CLINICAL INFORMATION
3.1.
TARGET SPECIES
Cats.
3.2.
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Active immunisation of cats:
−
to reduce the clinical signs caused by infection with feline
calicivirus (FCV) and feline
rhinotracheitis virus (FVR),
−
to prevent the clinical signs, leucopenia and virus excretion caused
by infection with feline
panleucopenia virus (FPLV).
Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks.
Duration of immunity for FCV and FVR: 1 year; for FPLV: 3 years.
3.3.
CONTRAINDICATIONS
See section 3.7
3.4.
SPECIAL WARNINGS
Vaccinate healthy animals only.
Maternal antibodies, which may persist up to the age of 9-12 weeks,
can have a negative influence on
the efficacy of vaccination. In the presence of maternal antibodies,
vaccination may not completely
prevent the clinical signs, leucopenia and virus excretion following
an FPLV infection. In such cases
where a relatively high level of maternally derived antibodies is
expected, the vaccination schedule
should be planned accordingly.
3.5.